MannKind Corporation (MNKD) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Mankind Corporation 3rd Quarter 2025 Financial Results Earnings Call. As a reminder, this call is being recorded on November 5th 2025 and will be available for playback on the Mankind Corporation website shortly after the conclusion of this call and available for approximately 90 days. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations. For further information on the company's risk factors, please see the form 10Q for the quarterly period ended September 30th, 2025, the earnings release, and the slides prepared for this presentation. Joining us today for Mankind are Chief Executive Officer Michael Castagna and Chief Financial Officer Chris Prentice. I'd now like to turn the conference over to Mr. Castagna. Please go ahead, sir. Good morning and thank you for joining our Q3 2025 earnings call. Let me start with the Q3 highlights. We delivered a record revenue of a quarter of $82 million. We also strengthened our portfolio with the acquisition of SC Pharmaceuticals. On the pipeline side, Afrez's supplemental BLA was accepted for review with a PDUFA date of Q2, 2026. We also saw strong performance from Tyveso DPI, which contributed $59 million in royalty and manufacturing-related revenue, reinforcing the durability of our revenue streams. Christopher will review the details of our third quarter results shortly. We're excited to have completed the acquisition of SC Pharmaceuticals and are pleased to welcome their talented team to Mankind. Together, we're focused on unlocking the full potential of Firo6 as well as the advancement of inhaled Bumetanide, AKA Mankind 701 for fluid overload and CKD an...